Microsoft Word - Letter to President Jean-Claude Juncker.docx

Report an error

Summary

AI-generated

This summary is written by a language model reading the source document. It is not the publisher's words and is not a substitute for the original.

Learn more about AI enrichment

A coalition of organizations urges the European Commission to strengthen its strategic approach to pharmaceuticals in the environment, citing the grave global health and economic threats of antimicrobial resistance. The authors call for broadening Good Manufacturing Practices to include environmental impacts, using Watch List data to identify priority substances under the Water Framework Directive, and implementing robust Environmental Risk Assessments for marketing authorizations.

Key insights

AI-generated

These insights are written by a language model reading the source document. They are not the publisher's words and are not a substitute for the original.

Learn more about AI enrichment
  • Antimicrobial resistance (AMR) is identified as a critical global threat, with annual deaths projected to increase from 700,000 currently to 10 million people worldwide by 2050.
  • The economic impact of drug-resistant infections is predicted to be severe, with potential global lost output of $100 trillion by 2050, while the EU specifically faces costs exceeding $1.5 billion in productivity losses and healthcare expenses.
  • The authors argue that the Good Manufacturing Practices (GMP) framework must be expanded to cover environmental impacts, noting that most EU pharmaceuticals are manufactured in third countries with poor environmental enforcement, which facilitates the spread of drug-resistant bacteria.
  • The letter calls for the use of surface water Watch List monitoring data to identify priority substances under the Water Framework Directive, rejecting the pharmaceutical industry's preference for a voluntary approach.
  • The authors demand that marketing authorizations for human and veterinary pharmaceuticals be conditional on robust Environmental Risk Assessments (ERAs), including compulsory assessments for products launched before 2006 (human) and 2005 (veterinary).

Cite the original document

APA
Changing Markets Foundation (2018). Microsoft Word - Letter to President Jean-Claude Juncker.docx. https://changingmarkets.org/wp-content/uploads/2023/10/Letter-to-President-Jean-Claude-Juncker.pdf
Chicago
Changing Markets Foundation. Microsoft Word - Letter to President Jean-Claude Juncker.docx. 2018. https://changingmarkets.org/wp-content/uploads/2023/10/Letter-to-President-Jean-Claude-Juncker.pdf.
Wikipedia
{{cite press release |author=Changing Markets Foundation |title=Microsoft Word - Letter to President Jean-Claude Juncker.docx |date=2 July 2018 |url=https://changingmarkets.org/wp-content/uploads/2023/10/Letter-to-President-Jean-Claude-Juncker.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}
BibTeX
@misc{changingmarketsfoundation2018microsoft, author = {{Changing Markets Foundation}}, title = {{Microsoft Word - Letter to President Jean-Claude Juncker.docx}}, publisher = {Changing Markets Foundation}, year = {2018}, month = jul, url = {https://changingmarkets.org/wp-content/uploads/2023/10/Letter-to-President-Jean-Claude-Juncker.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }

Full text

Collected · Record updated